In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
To establish an economically viable solvent extraction process, it is essential for the extractant to have low solubility in the aqueous phase and understanding the factors influencing this solubility is equally crucial
We excluded participants who left at least 1 TTO or VAS question blank or incomplete (noncompleters) and respondents who reported the same answer for all TTO scenarios (nontraders)
#1: Number of Treatment Areas Because of its versatility, liposuction can apply to numerous body areas, from the neck to the thighs and beyond
Liu B, Liu Y, Li S, Chen P, Zhang J, Feng L
